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Abstract
Background: Chronic cluster headache (CH) is a debilitating disorder for which few well-controlled studies demon-
strate effectiveness of available therapies. Non-invasive vagus nerve stimulation (nVNS) was examined as adjunctive
prophylactic treatment of chronic CH.
Methods: PREVA was a prospective, open-label, randomised study that compared adjunctive prophylactic nVNS (n¼ 48)
with standard of care (SoC) alone (control (n¼ 49)). A two-week baseline phase was followed by a four-week ran-
domised phase (SoC plus nVNS vs control) and a four-week extension phase (SoC plus nVNS). The primary end point
was the reduction in the mean number of CH attacks per week. Response rate, abortive medication use and safety/
tolerability were also assessed.
Results: During the randomised phase, individuals in the intent-to-treat population treated with SoC plus nVNS (n¼ 45)
had a significantly greater reduction in the number of attacks per week vs controls (n¼ 48) (5.9 vs 2.1, respectively)
for a mean therapeutic gain of 3.9 fewer attacks per week (95% CI: 0.5, 7.2; p¼ 0.02). Higher 50% response rates were
also observed with SoC plus nVNS (40% (18/45)) vs controls (8.3% (4/48); p< 0.001). No serious treatment-related
adverse events occurred.
Conclusion: Adjunctive prophylactic nVNS is a well-tolerated novel treatment for chronic CH, offering clinical benefits
beyond those with SoC.
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Introduction
Cluster headache (CH) is a trigeminal autonomic
cephalalgia with an estimated lifetime prevalence of
124 per 100,000 adults (1). CH attacks are unilateral,
with severe pain located in periorbital, retro-orbital and
temporal regions. Pain peaks within minutes, may last
up to three hours if untreated (2,3) and is usually
accompanied by cranial autonomic symptoms (e.g. con-
junctival injection or lacrimation, nasal congestion or
rhinorrhoea, periorbital oedema) and agitation (1,2). If
attacks occur for >1 year without pain-free remission
lasting 1 month, CH is classified as chronic (3).
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Abortive therapy aims to reduce the severity and
duration of CH attacks (4). First-line abortive treat-
ments include inhaled oxygen (2,5) and subcutaneous
(SC) or intranasal triptans (2,4,6). Verapamil is a
mainstay of prophylactic therapy; however, it is not
approved for this indication, and only two rando-
mised controlled trials with level-C evidence support
its use (4). Although other pharmacologic interven-
tions (e.g. lithium, oral steroids, valproic acid, topir-
amate, ergotamine, suboccipital steroid injections)
have been investigated, most lack compelling evi-
dence to support their use (2,4,7); suboccipital steroid
injections have demonstrated efficacy as adjunctive
prophylactic therapy for CH in patients receiving
verapamil (8).
Vagus nerve stimulation (VNS) has been investi-
gated as adjunctive or first-line treatment for CH (9).
The strong parasympathetic activation that occurs
during CH attacks (10) supports the rationale for
nVNS therapy. Early data suggested that inhibition of
pain by VNS occurs by inhibition of vagal afferents to
the trigeminal nucleus caudalis (TNC) (11). More
recent evidence suggests that VNS may also inhibit
pain by modulating inhibitory neurotransmitter release,
leading to decreased TNC glutamate levels (12,13). The
Prevention and Acute Treatment of Chronic Cluster
Headache (PREVA) trial is the first randomised con-
trolled study that examined non-invasive VNS (nVNS;
gammaCore) as adjunctive prophylactic therapy for
CH attacks in patients with chronic CH.
Methods
Study design
This prospective, multicentre, open-label, randomised,
controlled, parallel-group study, conducted from
October 2012 through March 2014, involved 10
European sites: five in Germany, three in the United
Kingdom, one in Belgium, and one in Italy. The
study was funded by electroCore, LLC, and was con-
ducted in accordance with principles and requirements
of the Declaration of Helsinki, Good Clinical Practices
and clinical trial registration (ClinicalTrials.gov
IdentiEer NCT01701245). All investigators obtained
institutional review board approval, and all partici-
pants provided written informed consent. The study
comprised a two-week baseline phase during which all
participants received only their individualised standard
of care (SoC); a four-week randomised phase during
which participants were randomly assigned 1:1 by
standard block design to receive either SoC plus
nVNS or SoC alone (control); and an optional four-
week extension phase during which all participants
received SoC plus nVNS (Figure 1).
Study population
Participants were aged 18 to 70 years and were diag-
nosed with chronic CH according to International
Classification of Headache Disorders criteria (3)
1 year before enrolment. Key exclusion criteria were
change in prophylactic medication type or dosage
<1 month before enrolment; history of intracranial/car-
otid aneurysm or haemorrhage; brain tumours/lesions;
significant head trauma; previous surgery or abnormal
anatomy at the nVNS treatment site; known or sus-
pected cardiac/cardiovascular disease; implantation
with electrical or neurostimulation devices; history of
carotid endarterectomy or vascular neck surgery;
implantation with metallic hardware; and recent history
of syncope or seizures.
Intervention
The nVNS device produced a low-voltage electrical
signal (5-kHz sine wave series that occurred for 1ms
and repeated every 40 ms (25Hz)). When applied
against the neck, the device delivered a maximum of
24V and 60mA output current while allowing stimula-
tion amplitude adjustment by the user. Two stainless
steel contact surfaces and conductive gel applied by the
user enabled delivery of stimulations. Mandatory nVNS
prophylaxis consisted of three 2-minute stimulations (i.e.
three doses) five minutes apart administered twice daily
(i.e. six doses per day) to the right side of the neck (right
vagal nerve). The first prophylactic treatment was
administered within one hour of waking; the second
was administered seven to 10 hours after the first treat-
ment. The number, duration, frequency, and timing of
doses were chosen according to previously reported
nVNS dosing parameters (9). Participants also had the
option of acutely treating CH attacks with three add-
itional nVNS doses at pain onset but were advised to
not administer prophylactic therapy within a two-hour
period after acute treatment. If the CH attack was not
aborted within 15 minutes after stimulation, individuals
were instructed to take abortive medications (e.g. SC
sumatriptan, inhaled oxygen and intranasal zolmitrip-
tan). Changes in SoC prophylactic medications (e.g. ver-
apamil, lithium, topiramate and corticosteroids) were
not permitted throughout the study.
Objectives, efficacy assessments and end points
The objective was to assess the efficacy of adjunctive
prophylactic nVNS therapy in chronic CH. The pri-
mary end point was the reduction in the mean
number of CH attacks per week, defined as the
number of attacks during the last two weeks of the
randomised phase minus the number of attacks
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during baseline divided by 2. Attack frequency was
evaluated during the last two weeks of the four-week
randomised phase to ensure sufficient time for nVNS to
demonstrate its full effect. Reductions in the mean
number of CH attacks per week were also evaluated
during the last two weeks of the extension phase.
Secondary efficacy end points included 50%
response rate (i.e. proportion of participants with
50% reduction in mean number of CH attacks per
week), abortive medication use and duration and inten-
sity of CH attacks that were acutely treated with nVNS.
The 50% response rate was assessed during the last
two weeks of the randomised phase and the last two
weeks of the extension phase. All other secondary end
points were assessed at baseline and during the last two
weeks of the randomised and extension phases.
Participant-completed headache diaries captured the
number of CH attacks, CH pain intensity (five-point
scale: none to very severe), CH duration and abortive
medication use. The EQ-5D-3L (14) and six-item
Headache Impact Test (HIT-6TM) (15) instruments
were used to assess quality of life (QoL) at the end of
baseline and at the end of both treatment phases.
Adherence to nVNS treatment was evaluated in each
phase by dividing the actual number of doses adminis-



































Figure 1. Participant disposition.
ITT: intent-to-treat; mITT: modified intent-to-treat; nVNS: non-invasive vagus nerve stimulation; SoC: standard of care.
aExclusions or discontinuations for more than one reason occurred in some individuals.
bRefer to the table below the figure for a breakdown of discontinuations by reason.
cOther reasons for discontinuation included inability to fulfil visits because of injury, inability to continue the study because of family
commitments, dissatisfaction with or discontinued use of the device, and noncompliance with study procedures.
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Safety, tolerability and perceptions of nVNS
Safety and tolerability were assessed by evaluating
adverse events (AEs), vital signs and physical exami-
nation results. Participants recorded AEs in their head-
ache diaries; additional AE information and vital sign/
physical examination results were obtained by the clin-
ical investigator at scheduled clinic visits. AEs were
summarised by frequency, treatment relatedness and
severity. Satisfaction with nVNS (five-point scale:
extremely satisfied to not at all satisfied), recommenda-
tion of the device to a family member or friend (yes/no),
and ease of device use (four-point scale: very easy to
very difficult) were evaluated at the end of the extension
phase.
Sample size determination
Enrolment of 90 individuals was planned, with an esti-
mated dropout rate of 10%. The mean frequency of
CH attacks at baseline was assumed to be 4.0 per
week. Predicted reductions in the number of CH
attacks per week were 50% for the SoC plus nVNS
group and 10% for the control group. A sample size
of 40 participants per treatment arm had 80% power to
detect between-group differences in mean change from
baseline using a two-sided test with a 0.05. An interim
analysis of sample size was performed after enrolment
of 30 people in each treatment group. Mean reductions
in the number of CH attacks per week for SoC plus
nVNS and control arms were 5.5 and 1.1, respectively
(common standard deviation (SD), 6.87); the effect size
was 0.65.
Statistical analyses
Safety and tolerability were assessed in the safety popu-
lation (i.e. all individuals assigned to treatment). The
intent-to-treat (ITT) population was defined as all par-
ticipants who had 1 efficacy recording in the headache
diary after randomisation. The modified ITT (mITT)
population was defined as participants who had meas-
urable observations across the respective study phases
being compared (i.e. baseline vs randomised phase,
baseline vs extension phase or randomised vs extension
phase). The reduction in the number of CH attacks per
week from baseline to the randomised phase (primary
end point) was assessed in the ITT population, for
which missing data were imputed to 0 (i.e. no change;
designated as treatment failures). The change in the
number of CH attacks from the randomised phase to
the extension phase was assessed in the mITT popula-
tion. The 50% response rate was assessed in the ITT
(with imputation to no response for missing data) and
mITT populations. Because no formal hypotheses were
associated with secondary outcomes (i.e. abortive medi-
cation use, QoL), these data were assessed in the mITT
population.
Analysis of variance and analysis of covariance (site
as covariate) were used to assess differences between
treatment groups for the primary end point and the
change in duration and intensity of CH attacks.
Within-participant differences in the number of CH
attacks and pain intensity ratings reported during the
randomised and extension phases were analysed using
the Wilcoxon rank sum test. Differences in response
rates between treatment groups were evaluated using
chi-square analysis without continuity correction.
Two-sided p values were calculated, and p< 0.05 was
considered statistically significant.
Results
Participant disposition, demographics and treat-
ment adherence
Of the 114 individuals enrolled and assessed at baseline,
97 were randomly assigned to treatment and consti-
tuted the safety population (SoC plus nVNS, n¼ 48;
control, n¼ 49); 92 continued into the extension phase
(SoC plus nVNS, n¼ 44; control, n¼ 48); and 70 com-
pleted the study (SoC plus nVNS, n¼ 33; control,
n¼ 37) (Figure 1). Of the 97 individuals in the safety
population, 93 met the criteria for inclusion in the ITT
population (SoC plus nVNS, n¼ 45; control, n¼ 48).
Because the mITT population relied on the availability
of measurable observations across the study phases
being compared, the number of participants who met
the criteria for inclusion in this population varied
among the individual end points.
Demographics and baseline characteristics were
similar between groups and were representative of the
overall CH population (2); use of SoC prophylactic
medications was also comparable between groups
(Table 1). In the ITT population, 64.4% (29/45) of indi-
viduals assigned to SoC plus nVNS were 80% adher-
ent to nVNS treatment during the randomised and
extension phases; 50% (24/48) of participants assigned
to control were 80% adherent to nVNS treatment
during the extension phase.
Effect of nVNS on CH attack frequency
In the ITT population (SoC plus nVNS, n¼ 45; control,
n¼ 48), participants receiving SoC plus nVNS during
the randomised phase had a greater reduction from
baseline (5.9; SE, 1.2) in the number of CH attacks
per week than those receiving control (2.1; SE, 1.2),
for a mean therapeutic gain of 3.9 fewer CH attacks per
week (95% confidence interval (CI): 0.5, 7.2; p¼ 0.02)
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(Figure 2). In the site-adjusted model, the mean thera-
peutic gain was 4.2 fewer headache attacks per week
(95% CI: 0.8, 7.5; p¼ 0.02).
To determine the efficacy of longer-term prophylactic
use of nVNS, the reduction in the number of CH attacks
during the extension phase was examined in the mITT
population. Individuals who continued using nVNS
through the extension phase (n¼ 30) reported an add-
itional reduction of two CH attacks per week (ran-
domised phase, 9.6; extension phase, 7.6; p< 0.001),
suggesting further benefit with continued use. Upon
addition of nVNS in the control group (n¼ 41) during
the extension phase,mITT individuals reported a signifi-
cant reduction of 3.3 CH attacks per week (randomised
phase, 15.7; extension phase, 12.4; p< 0.001).
50% Response rates
Among participants in the ITT population, a signifi-
cantly higher 50% response rate during the ran-
domised phase was observed in the SoC plus nVNS
group (40% (18/45)) than in the control group (8.3%
(4/48)) (p< 0.001) (Figure 3(a)). Similarly, the response
rate in the mITT population (SoC plus nVNS, n¼ 37;
control, n¼ 47) was also significantly higher for individ-
uals receiving SoC plus nVNS (48.6% (18/37)) than for
the control group (8.5% (4/47)) (p< 0.001; Figure 3(b)),
suggesting that participants who remained in the study
continued to respond. During the extension phase,
50% response rates in ITT individuals who continued
adjunctive nVNS and those who began nVNS were
28.9% and 16.7%, respectively (Figure 3(a)).
The response rate for mITT individuals continuing
treatment with nVNS (Figure 3(b)) through the end of
the extension phase was 46.4% (13/28). The response
rate for mITT individuals in the control arm who parti-
cipated in the extension phase (n¼ 37) increased from
8.5% (4/47) during the randomised phase to 21.6%
(8/37) with the addition of nVNS in the extension phase.
Abortive medication use
The number of times abortive medications were used in
the mITT population during the last two weeks of each
study phase is presented in Figure 4. During the rando-
mised phase, a 57%decrease in the frequency of abortive
medication use was noted in the SoC plus nVNS group
(¼15 (95%CI:22.8,7.2); p< 0.001). In contrast,
individuals assigned to the control group did not experi-
ence a substantial reduction in abortive medication use
(¼2 (95% CI: 9.4, 5.4); p¼ 0.59). Changes in
abortive medication use among participants assigned
to SoC plus nVNS were driven by >60% reductions in
the use of SC sumatriptan (¼4.4 (95% CI: 7.6,
1.2); p¼ 0.007) and inhaled oxygen (¼10.8
(95% CI: 19.4, 2.2); p¼ 0.02) (Figure 4(a)); such






Age, y, mean (SD) 45.4 (11.0) 42.3 (11.0)
Sex, n (%)
Male 34 (71) 33 (67)
Time since onset of chronic CH disorder, y, mean (SD)a 4.7 (3.9) 5.0 (3.7)
CH attack duration, min, mean (SD)
With acute pharmacologic medications/oxygenb 27.4 (19.8) 29.3 (29.9)
Without acute pharmacologic medications/oxygenc 95.2 (57.7) 103.3 (66.8)
Number of CH attacks in the four weeks before enrolment, mean (SD)c 67.3 (43.6) 73.9 (115.8)
Use of prophylactic medications for CH, n (%)
Verapamil/verapamil hydrochloride 25 (52) 26 (53)
Lithium/lithium carbonate 6 (13) 9 (18)
Topiramate 7 (15) 7 (14)
Corticosteroids 2 (4) 2 (4)
Use of pharmacologic medications/oxygen for the acute treatment of CH, n (%)
Pharmacologic medications 43 (90) 44 (90)
Oxygen 32 (67) 34 (69)
CH: cluster headache; nVNS: non-invasive vagus nerve stimulation; SD: standard deviation; SoC: standard of care; y: years.
aData were missing for two participants in the control group.
bData were missing for one participant in the control group.
cData were missing for one participant in the SoC plus nVNS group.
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reductions were maintained during the extension phase
(Figure 4(b)). Among individuals previously assigned to
the control group, adjunctive prophylactic nVNS during
the extension phase did not result in a significant reduc-
tion in the use of any abortive medication (¼3.4
(95% CI: 11.5, 4.7); p¼ 0.40).
Use of nVNS as abortive therapy
During the randomised phase, 93.8% (45/48) of indi-
viduals assigned to SoC plus nVNS acutely treated
1 CH attack with nVNS; during the extension
phase, 68.2% (30/44) and 83.3% (40/48) assigned to
SoC plus nVNS and control, respectively, acutely trea-
ted 1 CH attack with nVNS. The optional use of
nVNS as abortive therapy for CH attacks had no
effect on CH attack duration or pain intensity (data
not shown).
QoL outcomes
Changes from baseline in the mean EQ-5D-3L index
score for the mITT population were greater for the
SoC plus nVNS group than for the control group
(Table 2), indicating a significant improvement with
nVNS (SoC plus nVNS minus control: ¼ 0.194
point (95% CI: 0.054, 0.334 point); p¼ 0.007). The
change in EQ-5D-3L index score for participants
receiving SoC plus nVNS (0.145 point) was above the
reported minimally important difference (MID; 0.074
point) (16) and was considered clinically meaningful.
Addition of nVNS in participants previously assigned
to the control group was associated with a clinically
meaningful change in EQ-5D-3L index score during
the extension phase (0.078 point (95% CI: 0.02, 0.18
point)) (Table 2).
In the randomised phase, the change from baseline
in the mean EQ-5D-3L visual analogue scale (VAS)
score was greater for the SoC plus nVNS group than
for the control group (Table 2) and reflected a signifi-
cant improvement with nVNS (SoC plus nVNS minus
control: ¼ 8.93 points (95% CI: 0.47, 17.39 points);
p¼ 0.039). During the extension phase, individuals who
were previously assigned to control also showed
improved VAS scores (Table 2). Although changes in
mean HIT-6 scores in the SoC plus nVNS group were
greater than those in the control group (Table 2) and
were above the reported MID (2.3 points) (17), abso-
lute mean HIT-6 scores suggested that CH attacks con-
tinued to have a substantial impact on QoL (data not
shown).
Safety, tolerability and perceptions of nVNS
A total of seven individuals discontinued participation
because of AEs (Table 3); only two AEs (depressed
mood and CH) occurred in >1 person. During the
two months of treatment, similar proportions of par-
ticipants in the SoC plus nVNS group (52% (25/48))








Figure 2. Mean change in the number of CH attacks per week: baseline vs the last two weeks of the randomised phase (ITT
population).
CH: cluster headache; ITT: intent-to-treat; nVNS: non-invasive vagus nerve stimulation; SoC: standard of care.
Values are presented as unadjusted means and were calculated from all participants with evaluable data.
p value corresponds to the difference in the change from baseline between treatment groups from an analysis of variance.
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AEs were mild or moderate (93% (108/116)). Among
participants assigned to SoC plus nVNS, 38% (18/48)
experienced AEs during the randomised phase and
25% (12/48) experienced AEs in the extension phase.
Among individuals assigned to control, 27% (13/49)
experienced AEs during the randomised phase and
24% (12/49) experienced AEs in the extension phase.
Overall, the most common AEs in any treatment group
were CH attacks, headache, nasopharyngitis, dizziness,
oropharyngeal pain, and neck pain.
Four people (two per treatment group) reported a
serious AE (SoC plus nVNS: cholecystitis and haema-
toma after scheduled surgery; control: genital herpes
simplex virus infection and exacerbation of CH;
Table 3); no serious AEs were considered related to



















































Figure 3. 50% Response to treatmenta.
(a) ITT population.
(b) mITT population.
CH: cluster headache; ITT: intent-to-treat; mITT: modified intent-to-treat; nVNS: non-invasive vagus nerve stimulation; SoC: standard
of care.
aProportion of individuals with 50% reduction in the mean number of CH attacks per week.
Data were calculated at the end of the treatment phases.
p values correspond to the difference in response rate between treatment groups.
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the study. During the randomised phase, 11 individuals
who received nVNS experienced 15 device-related AEs,
13 (87%) of which were mild or moderate; severe device-
related depression andmalaise were noted in one person.
Two participants who continued treatment with nVNS
during the extension phase experienced mild device-
related AEs. Mild or moderate device-related AEs
occurred in seven participants who began nVNS therapy
during the extension phase. Physical examinations and
vital sign assessments at the end of the extension phase
revealed no treatment-related abnormalities.
At the end of the study, 65% of participants (62/96)
stated that they would recommend the nVNS device to
others, >75% of individuals rated nVNS as easy to use


























Figure 4. Abortive medication use (mITT population).
(a) Use of sumatriptan and oxygen: baseline vs the last two weeks of the randomised phase.
(b) Use of sumatriptan and oxygen: last two weeks of the randomised phase vs the last two weeks of the extension phase.
mITT: modified intent-to-treat; nVNS: non-invasive vagus nerve stimulation; SoC: standard of care.
Values are presented as means and were calculated from all participants with evaluable data.
Error bars denote standard error of the mean.
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Discussion
Given the limited understanding of the pathophysi-
ology of CH, management strategies have been derived
primarily from empirical evidence (10,18,19).
Prophylactic therapies for CH have been established
on the basis of clinical experience, with very few well-
conducted randomised clinical trials providing high-
level supportive evidence (4,18). To date, PREVA is
the largest prospective, randomised, controlled trial
that examined the clinical benefit of prophylactic
nVNS therapy in a treatment-refractory chronic CH
Table 3. Safety and tolerability (safety population).
Incidence of AEs SoC plus nVNS (n¼ 48) Control (n¼ 49)
Participants with 1 AE, n (%) 25 (52) 24 (49)
Participants with 1 AE leading to discontinuation, n (%) 3 (6)a 4 (8)b
Participants reporting any serious AEc, n (%) 2 (4) 2 (4)
Participants with 1 device-related AE, n (%) 13 (27)d 7 (14)e
AEs reported in 5% of participants in any treatment group, n (%)
Nervous system disorders
CH attack 1 (2)f 5 (10)f
Dizziness 3 (6)f 3 (6)
Headache 4 (8) 1 (2)
Infections and infestations
Nasopharyngitis 1 (2) 4 (8)
Respiratory, thoracic, and mediastinal disorders
Oropharyngeal pain 3 (6)f 1 (2)
Musculoskeletal and connective tissue disorders
Neck pain 3 (6) 0
AE: adverse event; CH: cluster headache; nVNS, non-invasive vagus nerve stimulation; SoC: standard of care.
aIncluded feeling hot, malaise, haematoma after scheduled surgery and depressed mood.
bIncluded chest pain, fatigue, depressed mood and CH.
cCholecystitis and haematoma after scheduled surgery were reported in two participants in the SoC plus nVNS group; genital herpes simplex virus
infection and exacerbation of CH were reported in two participants in the control group.
dIncludes depressed mood, malaise, oropharyngeal pain, CH, paraesthesia, muscle twitching, muscle spasms, feeling hot, hot flush, acne, pain, throat
tightness, dizziness, hyperhidrosis, toothache, decreased appetite and skin irritation.
eIncluded erythema, facial oedema, CH, chest pain, fatigue, depressed mood, pruritus, musculoskeletal stiffness and parosmia, all of which occurred
during the extension phase.
fIncluded 1 AE determined by causality assessment to be related to treatment.
Table 2. Quality of life outcomes (mITT population).
QoL measures
SoC plus nVNS Control SoC plus nVNS Control
Mean change from baseline to randomised phasea,b Mean change from baseline to extension phasec,d
EQ-5D-3L Index score 0.145e 0.049 0.155 0.078
EQ-5D-3L VAS score 9.20f 0.27 10.79 4.36
HIT-6 score 2.78 0.47 3.28 2.77
HIT-6: 6-item Headache Impact Test; mITT: modified intent-to-treat; nVNS: non-invasive vagus nerve stimulation; QoL: quality of life; SoC: standard of
care; VAS: visual analogue scale.
aNumber of participants evaluated for EQ-5D-3L index score: SoC plus nVNS, n¼ 35, and control, n¼ 46; EQ-5D-3L VAS score: SoC plus nVNS,
n¼ 35, and control, n¼ 45.
bNumber of participants evaluated for HIT-6 score: SoC plus nVNS, n¼ 37, and control, n¼ 45.
cNumber of participants evaluated for EQ-5D-3L index score: SoC plus nVNS, n¼ 34, and control, n¼ 40; EQ-5D-3L VAS score: SoC plus nVNS,
n¼ 34, and control, n¼ 39.
dNumber of participants evaluated for HIT-6 score: SoC plus nVNS, n¼ 36, and control, n¼ 39.
ep¼ 0.007 vs control.
fp¼ 0.039 vs control.
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population. This study met its primary end point by
demonstrating that daily adjunctive prophylactic
nVNS therapy significantly reduced the number of
CH attacks per week, which presumably led to substan-
tial reductions in abortive medication use and meaning-
ful improvements in QoL. Compared with participants
who received nVNS treatment during the randomised
phase, individuals who began nVNS therapy during the
extension phase had a lower response rate. Findings in
the mITT population showed that people who persisted
in the study continued to respond to nVNS, which is
consistent with the reported effects of VNS in epilepsy
(20). Treatment with nVNS was safe and well tolerated,
with no serious device-related AEs.
Study limitations include the lack of a placebo/sham
device, an open-label study design, the short treatment
duration and the use of patient-reported outcomes. No
placebo arm was incorporated into the study because a
suitable placebo/sham device had not yet been designed.
In lieu of a placebo/sham arm, SoCwas deemed themost
appropriate control treatment that was reflective of a
real-world clinical scenario. The open-label study
design and short treatment duration may have contrib-
uted to a placebo effect in both treatment groups. The
16.7% response rate in the control group during the
extension phase may partially reflect a placebo response
to nVNS. The initial response experienced in the control
group during the randomised phase may have also
impacted the capacity for a meaningful response to
nVNS during the extension phase. Additionally, fewer
individuals in the control arm (50%) than in the nVNS
arm (64.4%) were highly adherent (80%) to prophy-
lactic nVNS, which may have further confounded
response rates and reductions in abortive medication
use in this group. Only patients with chronic, treat-
ment-refractory CH were included because of their
stable CH attack frequency and intensity. A 2.5-month
study duration was deemed sufficient to observe a treat-
ment effect. Treatment response in favour of nVNS was
consistent across ITT, mITT and per-protocol popula-
tions (per-protocol populationwas defined as participants
in the mITT population who had 12 days of observa-
tion in the randomised phase and no major protocol
violation; data not shown). Because no CH-specific
QoL instruments exist, the EQ-5D-3L and HIT-6 meas-
ures were considered most appropriate, and nVNS
prophylaxis resulted in meaningful improvements for
both measures. The apparent lack of effect of acute
nVNS therapy on CH duration or severity is consistent
with findings in the chronic CH population that were
reported in a recent study of acute nVNS therapy for
CH (21,22). The nVNS adherence rates in this study
(50%–64%) are consistent with those reported for
prophylactic non-invasive neuromodulation in migraine
(23) and are considered meaningful given that twice-
daily nVNS requires more effort and participation
than a conventional oral medication regimen.
Current prophylactic treatments for CH are limited,
with verapamil and lithium being used most often.
High-dose verapamil is associated with serious cardio-
vascular effects (e.g. arrhythmias, bradycardia,
oedema) and lethargy (24,25); AEs of lithium therapy
include tremor, hypothyroidism and renal dysfunction
(19,26). Thus, both therapies may necessitate close
patient monitoring, which in turn may incur substantial
costs. Long-term occipital nerve stimulation (ONS) has
been shown to reduce attack frequency in patients with
chronic CH, but its use is hampered by the invasive
nature of the procedure and high incidence of AEs
(27–30). Deep brain stimulation (DBS) had no effect
on attack frequency in patients with chronic CH
during the two-month randomised phase of a double-
blind crossover study (31); however, >50% reduction
in weekly CH attack frequency was noted after
10 months of continuous open-label DBS. In studies
of ONS and DBS, implantation-related infections
(28,29,31), intracranial haemorrhage (32), electrode/
lead displacement (27,29,30), device-related technical
problems or other health complications (27,29,31) and
lead revisions (30) have been reported. Moreover, the
per-patient costs for these therapies are extremely high
(27,33). Sphenopalatine ganglion stimulation was
found to be effective in the acute treatment of chronic
CH; however, procedural complications, infections and
other implantation-related AEs were reported (34).
Thus, the inherent risks associated with currently avail-
able implanted neuromodulation devices and the side
effects of prophylactic medications for chronic CH
highlight the need for alternative therapies. To this
end, nVNS serves as a safe and effective non-invasive
therapy that could be easily incorporated into the exist-
ing treatment regimens of patients with chronic CH.
We conclude that findings from PREVA demon-
strate the clinical relevance of nVNS in patients with
treatment-refractory chronic CH. Adjunctive prophy-
lactic therapy with nVNS can safely reduce CH attack
frequency and may yield clinical benefits beyond those
afforded by SoC treatment.
PREVA Study Group
Investigators are listed by country. 1. Germany:
Migraine and Headache Clinic, Königstein – Charly
Gaul, MD (principal investigator), Ronald Brand,
MD (subinvestigator); University Hospital-Essen,
Essen – Hans-Christoph Diener, MD, PhD (principal
investigator), Kasja Rabe (subinvestigator), Holle
Dagny (subinvestigator), Steffen Nägel, MD (subinves-
tigator), Maja Bak, MD (subinvestigator); Ludwig
Maximilian University of Munich, Munich – Andreas
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Straube, MD (principal investigator), Bernhard Blum,
MD (subinvestigator), Ruth Ruscheweyh, MD (subin-
vestigator), Ozan Eren, MD (subinvestigator);
Department of Neurology, Charité University
Hospital, Berlin – Uwe Reuter, MD (principal investi-
gator), Heike Israel-Willner, MD (subinvestigator),
Lars Neeb, MD (subinvestigator); Krankenhaus
Lindenbrunn, Lindenbrunn – Stefan Evers, MD, PhD
(principal investigator); 2. United Kingdom: The
Walton Centre for Neurology and Neurosurgery,
Liverpool – Nicholas Silver, MBBS, PhD (principal
investigator), Helen Banks, MD (subinvestigator),
Heike Arndt, MD (subinvestigator); The Southern
General Hospital, Glasgow – Alok Tyagi, MD (princi-
pal investigator); Hull Royal Infirmary, Hull – Fayyaz
Ahmed, MD (principal investigator), Anwar Osman,
MD (subinvestigator); 3. Belgium: Liège University,
Liège – Delphine Magis, MD, PhD (principal investi-
gator), Jean Schoenen, MD (subinvestigator); 4. Italy:
Sant’Andrea Hospital, Sapienza University of Rome,
Rome – Paolo Martelleti, MD (principal investigator),
Andrea Negro, MD (subinvestigator).
Article highlights
1. Adjunctive prophylactic non-invasive vagus nerve stimulation (nVNS) therapy reduced the number of clus-
ter headache (CH) attacks per week and use of abortive medication and improved quality of life (QoL) in
individuals with chronic CH.
2. Treatment with nVNS was safe and well tolerated.
3. In patients with chronic CH, adjunctive prophylactic nVNS may provide clinical benefits beyond those
derived from their current standard of care (SoC).
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